Literature DB >> 21796499

A method of adjusting SUV for injection-acquisition time differences in (18)F-FDG PET imaging.

Eric Laffon1, Henri de Clermont, Roger Marthan.   

Abstract

OBJECTIVE: A time normalisation method of tumour SUVs in (18) F-FDG PET imaging is proposed that has been verified in lung cancer patients.
METHODS: A two-compartment model analysis showed that, when SUV is not corrected for (18) F physical decay (SUV(uncorr)), its value is within 5% of its peak value (t = 79 min) between 55 and 110 min after injection, in each individual patient. In 10 patients, each with 1 or more malignant lesions (n = 15), two PET acquisitions were performed within this time delay, and the maximal SUV of each lesion, both corrected and uncorrected, was assessed.
RESULTS: No significant difference was found between the two uncorrected SUVs, whereas there was a significant difference between the two corrected ones: mean differences were 0.04 ± 0.22 and 3.24 ± 0.75 g.ml(-1), respectively (95% confidence intervals). Therefore, a simple normalisation of decay-corrected SUV for time differences after injection is proposed: SUV(N) = 1.66 SUV(uncorr), where the factor 1.66 arises from decay correction at t = 79 min.
CONCLUSIONS: When (18) F-FDG PET imaging is performed within the range 55-110 min after injection, a simple SUV normalisation for time differences after injection has been verified in patients with lung cancer, with a ±2.5% relative measurement uncertainty.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796499     DOI: 10.1007/s00330-011-2204-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  A method to quantify at late imaging a release rate of 18F-FDG in tissues.

Authors:  Eric Laffon; Michèle Allard; Roger Marthan; Dominique Ducassou
Journal:  C R Biol       Date:  2005-08       Impact factor: 1.583

2.  Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.

Authors:  Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

Review 3.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

Review 6.  Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Authors:  Rodney J Hicks
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 7.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

8.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.

Authors:  P Lindholm; H Minn; S Leskinen-Kallio; J Bergman; U Ruotsalainen; H Joensuu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

9.  A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.

Authors:  P Som; H L Atkins; D Bandoypadhyay; J S Fowler; R R MacGregor; K Matsui; Z H Oster; D F Sacker; C Y Shiue; H Turner; C N Wan; A P Wolf; S V Zabinski
Journal:  J Nucl Med       Date:  1980-07       Impact factor: 10.057

10.  Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.

Authors:  H Minn; K R Zasadny; L E Quint; R L Wahl
Journal:  Radiology       Date:  1995-07       Impact factor: 11.105

View more
  4 in total

1.  Adjustment of vascular 2-deoxy-2-[18F]fluoro-D-glucose uptake values over time through a modeling approach.

Authors:  Pavlos P Kafouris; Iosif P Koutagiar; Alexandros T Georgakopoulos; Nikoletta K Pianou; Marinos G Metaxas; George M Spyrou; Constantinos D Anagnostopoulos
Journal:  Int J Cardiovasc Imaging       Date:  2019-01-31       Impact factor: 2.357

2.  Variability of ¹⁸F-FDG-positive lung lesion volume by thresholding.

Authors:  Eric Laffon; Henri de Clermont; Roger Marthan
Journal:  Eur Radiol       Date:  2012-10-20       Impact factor: 5.315

3.  Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.

Authors:  Diomidis Botsikas; Anastasia Kalovidouri; Minerva Becker; Michele Copercini; Dahila Amal Djema; Alexandre Bodmer; Sindy Monnier; Christoph D Becker; Xavier Montet; Benedicte M A Delattre; Osman Ratib; Valentina Garibotto; Claire Tabouret-Viaud
Journal:  Eur Radiol       Date:  2015-10-17       Impact factor: 5.315

4.  Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.

Authors:  Laure Fournier; Lioe-Fee de Geus-Oei; Daniele Regge; Daniela-Elena Oprea-Lager; Melvin D'Anastasi; Luc Bidaut; Tobias Bäuerle; Egesta Lopci; Giovanni Cappello; Frederic Lecouvet; Marius Mayerhoefer; Wolfgang G Kunz; Joost J C Verhoeff; Damiano Caruso; Marion Smits; Ralf-Thorsten Hoffmann; Sofia Gourtsoyianni; Regina Beets-Tan; Emanuele Neri; Nandita M deSouza; Christophe M Deroose; Caroline Caramella
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.